Cite
Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2021;399(10319):36-49doi: 10.1016/S0140-6736(21)02718-5.
Stuart, A. S. V., Shaw, R. H., Liu, X., Greenland, M., Aley, P. K., Andrews, N. J., Cameron, J. C., Charlton, S., Clutterbuck, E. A., Collins, A. M., Darton, T., Dinesh, T., Duncan, C. J. A., England, A., Faust, S. N., Ferreira, D. M., Finn, A., Goodman, A. L., Green, C. A., Hallis, B., Heath, P. T., Hill, H., Horsington, B. M., Lambe, T., Lazarus, R., Libri, V., Lillie, P. J., Mujadidi, Y. F., Payne, R., Plested, E. L., Provstgaard-Morys, S., Ramasamy, M. N., Ramsay, M., Read, R. C., Robinson, H., Screaton, G. R., Singh, N., Turner, D. P. J., Turner, P. J., Vichos, I., White, R., Nguyen-Van-Tam, J. S., Snape, M. D. (2022). Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet (London, England), 399(10319), 36-49. https://doi.org/10.1016/S0140-6736(21)02718-5
Stuart, Arabella S V, et al. "Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial." Lancet (London, England) vol. 399,10319 (2022): 36-49. doi: https://doi.org/10.1016/S0140-6736(21)02718-5
Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Darton T, Dinesh T, Duncan CJA, England A, Faust SN, Ferreira DM, Finn A, Goodman AL, Green CA, Hallis B, Heath PT, Hill H, Horsington BM, Lambe T, Lazarus R, Libri V, Lillie PJ, Mujadidi YF, Payne R, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Screaton GR, Singh N, Turner DPJ, Turner PJ, Vichos I, White R, Nguyen-Van-Tam JS, Snape MD. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2022 Jan 01;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 06. PMID: 34883053; PMCID: PMC8648333.
Copy
Download .nbib